Alphamab Oncology

Alphamab Oncology, established in 2008, focuses on the research and industrialization of antibody and protein macromolecular drugs. With the vision of providing Chinese patients with the most advanced international therapeutic drugs, guided by cutting-edge international technologies and products, and driven by technological innovation, Alphamab Oncology has built a distinguished reputation in the biopharmaceutical R&D field.The company owns a comprehensive macromolecular drug R&D technology platform and has established a complete R&D function chain covering early screening of macromolecular drugs, cell engineering, cell line construction, pilot studies, scale-up, quality research, non-clinical and clinical drug research, and regulatory submission. To date, the company has obtained clinical research approvals for 8 Class I biological products and 5 biosimilars, with 3 varieties included in the National Major New Drug Creation Project. The company has also transferred over 30 biotechnologies and products to numerous pharmaceutical enterprises in China, significantly advancing the industrialization of biomedicine in Suzhou, Jiangsu, and throughout China.